All Stories

  1. Diverging trends and persistent inequities in cirrhosis burden across sub-Saharan Africa: projections to 2040
  2. Harnessing the oral microbiome in chronic liver disease: mechanisms, therapeutic modulation and translational frontiers
  3. A multi-strain probiotic modulates gut microbiome composition, intestinal barrier integrity and inflammation in a multi-compartmental in vitro gut model of decompensated alcohol-related advanced chronic liver disease
  4. Enhancing infection diagnostics in advanced chronic liver disease: harnessing clinical metagenomics for rapid pathogen and antimicrobial resistance detection
  5. Microbial collagenase activity is linked to oral–gut translocation in advanced chronic liver disease
  6. Decoding the microbiome and resistome of advanced chronic liver disease through long-read metagenomics
  7. Gene-centric metagenomic analyses reveal microbiome functional insights into diseases
  8. Plasmin-mediated proteolysis of von Willebrand factor in patients with acute and chronic liver disease
  9. FMT for hepatic encephalopathy? The THEMATIC trial aims to make it a ‘no brainer’
  10. Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults
  11. Lipidomics-based Plasma Signature of Alcohol-Related Hepatitis Linked to Short-Term Mortality
  12. Enhanced Computational and Experimental Approaches for Comparative Analysis of the Human Mycobiome
  13. Decompensated Liver Cirrhosis Research Network (UK-CLIF): Building consensus for hepatology trials in the UK
  14. microRNA associated with hepatocyte injury and systemic inflammation may predict adverse outcomes in cirrhotic patients
  15. Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial resistance
  16. Limitations of current techniques in clinical antimicrobial resistance diagnosis: examples and future prospects
  17. OS-070 Faecal microbiota transplantation in patients with cirrhosis, reduces antimicrobial resistance and enteric pathogen carriage, and enhances intestinal barrier function, associated with bacteriophage remodelling
  18. THU-317 Alcohol-related hepatitis is associated with a distinctive pattern of disordered bile acid metabolism and reduced bile acid transporter expression
  19. Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial
  20. Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: Study protocol for a randomised controlled trial
  21. Von Willebrand factor as a predictor of mortality in acute‐on‐chronic liver failure: Do not throw out the baby with the bathwater
  22. Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant
  23. Fibrin clots from patients with acute-on-chronic liver failure are weaker than those from healthy individuals and patients with sepsis without underlying liver disease
  24. Von Willebrand factor is an independent predictor of short‐term mortality in acutely ill patients with cirrhosis
  25. Pathogenic entero- and salivatypes harbour changes in microbiome virulence and antimicrobial resistance genes with increasing chronic liver disease severity
  26. In vivo generation of thrombin in patients with liver disease without apparent evidence of activation of the intrinsic or extrinsic pathway of coagulation
  27. Impact of liver failure on the circulating extracellular vesicle miRNA repertoire
  28. Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure
  29. AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate Cells
  30. Carvedilol in patients with compensated cirrhosis: the ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices
  31. General practitioner perspectives on factors that influence implementation of secondary care-initiated treatment in primary care: Exploring implementation beyond the context of a clinical trial
  32. P26 Circulating markers of neutrophil extracellular traps are associated with excessive coagulation activation in decompensated cirrhosis and acute-on-chronic liver failure
  33. P25 Rapid Infection Diagnostics in Cirrhosis (RIDiC): a novel molecular-based approach to address the ever increasing challenge of antimicrobial resistant infections in decompensated cirrhosis and acute-on-chronic liver failure
  34. P39 Systemic inflammation associated microRNA as novel biomarkers for clinical decompensation in patients with cirrhosis
  35. Images of the month 1: Histoacryl glue embolisation to the right ventricle following treatment for gastric varices
  36. Using a theory-informed approach to explore patient and staff perspectives on factors that influence clinical trial recruitment for patients with cirrhosis and small oesophageal varices
  37. Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates
  38. IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis
  39. Prevalence of Bleeding and Thrombosis in Critically Ill Patients with Chronic Liver Disease
  40. Aberrant hepatic trafficking of gut‐derived T‐cells is not specific to primary sclerosing cholangitis
  41. Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial
  42. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19
  43. The Lipopolysaccharide-Sensing Caspase(s)-4/11 Are Activated in Cirrhosis and Are Causally Associated With Progression to Multi-Organ Injury
  44. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute‐on‐Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid–Dependent Monocyte Activation
  45. Hemostatic balance in acute‐on‐chronic liver failure
  46. P225 Partial splenic artery embolisation for portal hypertension – a single centre experience
  47. Global hemostatic status in patients with acute‐on‐chronic liver failure and septics without underlying liver disease
  48. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
  49. Modulating the gut–liver axis and the pivotal role of the faecal microbiome in cirrhosis
  50. Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in advanced cirrhosis
  51. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis
  52. Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay
  53. Antimicrobial resistance in chronic liver disease
  54. Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute‐on‐Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival
  55. P: 71 Faecal Cytokine Profiling Provides Novel Insights Into Intestinal Barrier Disruption and Bacterial Translocation in Acute Decompensation of Cirrhosis
  56. P: 12 PROFIT: PROspective, Randomised Placebo-controlled Feasibility Trial of Faecal Microbiota Transplantation in Cirrhosis Interim Analysis
  57. P: 38 Rifaximin Reduces the Incidence of Spontaneous Bacterial Peritonitis, Variceal Bleeding and All-cause Admissions in Patients on the Liver Transplant Waiting List
  58. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list
  59. PS-174-Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis
  60. PS-144-Autotaxin mediates lipid dysregulation in acute-on-chronic liver failure, promoting persistence of systemic inflammation via lysophosphatidic acid-mediated monocyte activation
  61. THU-052-Immunometabolic profiling of ascites from patients with acute-on-chronic liver failure reveals increased MerTK+ immunosuppressive myeloid cells and cell death markers with preferential lipid metabolism compared to cirrhosis without organ failure
  62. THU-055-Improved stratification of liver failure syndromes using broad-panel bile acid LCMS phenotyping demonstrates novel pathways of dysregulation in tertiary bile acids in acute-on-chronic liver failure
  63. FRI-099-PD-1+ monocytes and macrophages contribute to impaired microbial clearance following acute liver failure
  64. PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial
  65. Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action
  66. PTH-106 Plasma S100A8/A9: a novel mechanistic biomarker in innate immune activation in acute-on-chronic liver failure
  67. In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis
  68. Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial)
  69. Platelet-leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion
  70. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure
  71. Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease
  72. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease
  73. CD14+CD15−HLA-DR−myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure
  74. MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure
  75. High-Speed Quantitative UPLC-MS Analysis of Multiple Amines in Human Plasma and Serum via Precolumn Derivatization with 6-Aminoquinolyl-N-hydroxysuccinimidyl Carbamate: Application to Acetaminophen-Induced Liver Failure
  76. MAIT cell dysfunctions correlate with markers of intestinal integrity in ALD patients
  77. Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis
  78. The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α
  79. Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure
  80. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial
  81. Altered Gut Microbial Profile is a Proponent of Bacterial Translocation in Acute-on-Chronic Liver Failure
  82. Dramatic Alterations of Anti-Bacterial Mait-Cell Network in Alcoholic Liver Disease
  83. Mer Tyrosine Kinase Regulates the Activation of Myeloid Cells and Innate Immune Responses in Acute-on-Chronic Liver Failure
  84. The Formation of Activated Platelet-Complexed Leukocytes is Augmented in Cirrhosis and Enhanced by Platelet Transfusion
  85. Clinical science workshop: targeting the gut-liver-brain axis
  86. Bile Acid Profiling and Quantification in Biofluids Using Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry
  87. Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure–Sequential Organ Failure Scoring System
  88. Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure
  89. Salivary microbiota-immune profiling in cirrhosis: Could this be the noninvasive strategy that will revolutionize prognostication in hepatology?
  90. P1329 : A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin in improving systemic inflammation and neutrophil malfunction in patients with cirrhosis and chronic hepatic encephalopathy (‘RIFSYS’)
  91. P1119 : Elevated levels of circulating bacterial DNA in alcoholic hepatitis identifies patients who will not respond to corticosteroid
  92. P1294 : Proof-of-principle evaluation of immunomodulatory drugs in promoting phagocytosis capacity in patients with liver failure
  93. P0168 : The impact on hospital resource utilisation of Rifaximin-alpha for hepatic encephalopathy in routine clinical practice: Real world data from seven UK liver centres
  94. O106 : Therapeutic plasma exchange modulates innate immune activation and improves outcome in patients with acute liver failure
  95. Patients With Acute-on-Chronic Liver Failure Have Increased Numbers of Regulatory Immune Cells Expressing the Receptor Tyrosine Kinase MERTK
  96. OC-029 Rifaximin Is Efficacious In The Treatment Of Chronic Overt Hepatic Encephalopathy: A Uk Liver Multi-centre Experience
  97. P314 CHARACTERISATION OF THE PLASMA METABOLIC PHENOTYPE OF ACUTE LIVER FAILURE BY H NMR SPECTROSCOPY
  98. P164 MONOCYTE EXHAUSTION: A MECHANISTIC EXPLANATION FOR SUSCEPTIBILITY TO INFECTION IN LIVER FAILURE
  99. Diabetes and the gastrointestinal tract
  100. Retrospective analysis of the impact of a low glycaemic index diet on hospital stay following coronary artery bypass grafting: a hypothesis